These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 14576114

  • 1. In vitro activities of garenoxacin (BMS-284756) against Haemophilus influenzae isolates with different fluoroquinolone susceptibilities.
    Pérez-Vázquez M, Román F, Aracil B, Cantón R, Campos J.
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3539-41. PubMed ID: 14576114
    [Abstract] [Full Text] [Related]

  • 2. Laboratory detection of Haemophilus influenzae with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to GyrA and ParC mutations.
    Pérez-Vázquez M, Román F, Aracil B, Cantón R, Campos J.
    J Clin Microbiol; 2004 Mar; 42(3):1185-91. PubMed ID: 15004073
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In vitro antibacterial activities of new fluoroquinolones against clinical isolates of haemophilus influenzae with ciprofloxacin-resistance-associated alterations in GyrA and ParC.
    Yoshizumi S, Takahashi Y, Watanabe Y, Okezaki E, Ishii Y, Tateda K.
    Chemotherapy; 2004 Dec; 50(6):265-75. PubMed ID: 15608441
    [Abstract] [Full Text] [Related]

  • 7. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
    Jones RN, Fritsche TR, Sader HS, Stilwell MG.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001.
    Christiansen KJ, Bell JM, Turnidge JD, Jones RN.
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2049-55. PubMed ID: 15155198
    [Abstract] [Full Text] [Related]

  • 12. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ, Walters M, Hisanaga T, Zhanel GG, Hoban DJ.
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [Abstract] [Full Text] [Related]

  • 13. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.
    Shultz TR, Tapsall JW, White PA.
    Antimicrob Agents Chemother; 2001 Mar; 45(3):734-8. PubMed ID: 11181352
    [Abstract] [Full Text] [Related]

  • 14. GyrA and/or ParC alterations of Haemophilus influenzae strains isolated from the urethra of men with acute urethritis.
    Kondo H, Ito S, Hatazaki K, Horie K, Nakane K, Mizutani K, Tsuchiya T, Yasuda M, Yokoi S, Nakano M, Deguchi T.
    J Infect Chemother; 2018 Mar; 24(3):232-235. PubMed ID: 29138021
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Antipneumococcal activity of DK-507k, a new quinolone, compared with the activities of 10 other agents.
    Browne FA, Bozdogan B, Clark C, Kelly LM, Ednie L, Kosowska K, Dewasse B, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3815-24. PubMed ID: 14638489
    [Abstract] [Full Text] [Related]

  • 18. Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin.
    Li X, Mariano N, Rahal JJ, Urban CM, Drlica K.
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4460-2. PubMed ID: 15504883
    [Abstract] [Full Text] [Related]

  • 19. In vitro pharmacodynamic evaluation of garenoxacin against quinolone-resistant Streptococcus pneumoniae.
    Fukuda Y, Takahata M, Sugiura Y, Shinmura Y, Nomura N.
    Int J Antimicrob Agents; 2012 Feb; 39(2):163-7. PubMed ID: 22088660
    [Abstract] [Full Text] [Related]

  • 20. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.
    Ince D, Zhang X, Silver LC, Hooper DC.
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3370-80. PubMed ID: 12384338
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.